Randomized Study of Zoledronic Acid Monohydrate in Combination Chemotherapy for High-Grade Osteosarcoma in Pediatric and Adult Patients

The primary objective of this study is to compare the **progression-free survival** of patients with high-grade **osteosarcoma** treated with combination chemotherapy and surgery, with or without the addition of **zoledronic acid**. This objective is clinically relevant as it aims to determine the efficacy of zoledronic acid in extending the time patients remain free from disease progression, which is crucial for improving long-term outcomes in osteosarcoma management.

Secondary objectives include:

• Assessing the impact of Zometa® on overall survival, histological response to chemotherapy, and the immediate and long-term tolerability of treatment, with a focus on renal tolerance, orthopedic complications, growth, bone density, and quality of life.
• Studying gene expression profiles in patients with varying responses, differences in tissue-array expression profiles between adult and pediatric patients, the prognostic value of angiogenesis markers such as FGF and VEGF, tumor antigen expression, the effect of Zometa® on lymphocyte populations, the consequences of bisphosphonate treatment on bone metabolism and growth, the impact of methotrexate pharmacogenetics, and the pharmacokinetics of Zometa® in children and young adults.

The clinical trial involves participants diagnosed with **high-grade osteosarcoma**, aiming to compare the progression-free survival of patients treated with combination chemotherapy and surgery, with or without zoledronic acid. The study population includes both male and female subjects, aged between 5 and 50 years, who have not previously undergone chemotherapy or radiotherapy for this or any other cancer. Participants must have no contraindications to the proposed treatments and must be capable of long-term follow-up. The trial includes a vulnerable population, and effective contraception is required for women of childbearing age. The sponsor has not provided information regarding the total number of participants. Participants were selected based on specific inclusion criteria, including histological confirmation of the disease and the ability to provide informed consent, with parental authorization required for minors. Membership in a social security scheme is also a prerequisite for participation.

The clinical trial is designed to evaluate the efficacy of **zoledronic acid** in combination with chemotherapy and surgery for patients with high-grade **osteosarcoma**. This is a Phase III, randomized, double-blind, controlled trial aimed at comparing progression-free survival between treatment groups. The trial is expected to run from April 23, 2007, to December 21, 2025. Participants will be randomly assigned to receive either the standard treatment regimen or the standard regimen plus zoledronic acid. The primary endpoint is event-free survival at three years, with secondary endpoints including overall survival, histological response, short-term and long-term toxicity, bone metabolism, and quality of life.

Study visits are structured to ensure comprehensive monitoring and data collection. The inclusion visit, or screening, will confirm eligibility based on criteria such as age (5 to 50 years), histologically proven high-grade osteosarcoma, and the absence of prior chemotherapy or radiotherapy for any cancer. Participants must also provide informed consent, with minors requiring parental authorization. Follow-up visits will occur at regular intervals to assess treatment response and monitor for adverse events. The end-of-study visit will evaluate the final outcomes and collect data on long-term effects.

Participant involvement is expected to last up to 10 years, depending on individual treatment response and disease progression. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any contraindications to continued treatment. The trial is conducted under strict ethical guidelines, ensuring participant safety and data integrity throughout the study duration.

The clinical trial involves the administration of **Zometa**, a pharmaceutical product containing **zoledronic acid monohydrate** as the active substance. Zometa is formulated as a **solution for infusion** and is provided in a concentration of 4 mg/100 ml. The medication is administered via **intravenous use**. The dosing regimen specifies a maximum daily dose of 4 mg, with a cumulative maximum dose of 40 mg over the treatment period. The treatment duration is limited to a maximum of 10 days. The product is manufactured by Phoenix Labs Unlimited Company and is classified under the ATC code M05BA08, indicating its use in bone disease treatment.

In this trial, Zometa is evaluated as an adjunct to standard-of-care therapy for patients with **osteosarcoma**. The study design includes a randomized trial component to assess the efficacy of Zometa in combination with chemotherapy and surgery, compared to chemotherapy and surgery alone. The primary objective is to compare the progression-free survival of patients receiving the combination therapy. Compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the protocol. No placebo or additional comparator treatments are specified in the trial design.

The efficacy of the clinical trial will be assessed primarily through the evaluation of **event-free survival** at 3 years. This primary endpoint will measure the time from randomization to the occurrence of any event such as disease progression, recurrence, or death. Secondary endpoints include overall survival, histological response, short-term and long-term toxicity as per NCI-CTC v3 criteria, bone metabolism, and quality of life. These parameters will provide a comprehensive assessment of the treatment's impact on patients with osteosarcoma.

Data collection will involve the use of validated scales and laboratory tests to ensure accuracy and reliability. The schedule for measuring these endpoints will be aligned with the trial's protocol, ensuring consistent and systematic data collection throughout the study duration. The analysis of these efficacy parameters will be conducted using appropriate statistical methods to determine the treatment's effectiveness in improving patient outcomes. The trial aims to compare the progression-free survival of patients treated with combination chemotherapy and surgery, with or without the addition of zoledronic acid.